Navigation Links
Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
Date:1/8/2008

- Clinical Trial Data and Emerging Clinical Practice Experience Support

HYLENEX Efficacy and Safety -

SAN DIEGO, Jan. 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced the Original Article publication of the INFUSE-LR clinical trial results in the Journal of Palliative Medicine, the official journal of the American Academy of Palliative Medicine (Thomas JR et al. J Pall Med. December 2007; 19(6): 1312-1320). The authors of this publication concluded from this volunteer subject study that clinically relevant fluid volumes can be rapidly delivered subcutaneously (Sub-Q) with HYLENEX in a well-tolerated manner without the need for an infusion pump. The findings suggest that this method of hydration could potentially replace intravenous infusions in many clinical settings and that further studies with HYLENEX, in patients, are warranted.

This call for additional study of HYLENEX in the clinical setting with patients has been addressed in an earlier publication in this same journal (Pirrello R et al. Initial Experiences with Subcutaneous Recombinant Human Hyaluronidase (rHuPH20). J Pall Med. 2007;10(4):861-864). In this first publication of actual clinical experience with a series of patients administered the HYLENEX marketed drug product, 32 patients were treated with HYLENEX in a hospice setting over a six-month period. Of these, 26 received HYLENEX to enhance Sub-Q infusion with standard hydration fluids (normal saline, 5% dextrose in saline, and 5% dextrose) for symptom control of delirium, myoclonus, and mild-to-moderate dehydration. Flow rates up to 500 mL/hour were attained without difficulty. Electrolyte replacement in hydration fluid was achieved without incident in several patients. In addition to use for fluid hydration, six patients received HYLENEX to enhance Sub-Q infusion of nine different medications (hydromorphine, lidocaine, dexamethasone, haloperidol, midazolam, ondansetron, famotidine, sufentanil, and glycopyrrolate), primarily because the medication dosage required Sub-Q flow rates greater than the standard 3 mL/hour. There were no significant adverse events (AEs); induration at the infusion site occurred in one patient receiving hydration and higher than expected serum lidocaine concentration was observed in another patient.

As previously reported (see February 8, 2006 Halozyme press release), the INcreased Flow Utilizing Subcutaneously-Enabled Lactated Ringer's clinical trial, or INFUSE-LR study, was designed to determine the Sub-Q infusion flow rate of Lactated Ringer's (LR) solution with and without HYLENEX, determine the Sub-Q infusion flow rate dose response to HYLENEX over one order of magnitude of dose, and assess safety and tolerability. This prospective, double-blind, randomized, placebo-controlled, dose-comparison study enrolled 54 volunteer subjects who received Sub-Q infusions simultaneously in both upper arms through 24-gauge catheters. The key findings from this study are:

In every subject tested in this study, HYLENEX injection preceding the

gravity-driven LR infusions enabled flow rates approximately 250% to 400%

faster than the infusions without HYLENEX. The overall mean flow rate for

Sub-Q infusion with HYLENEX was 464 mL/hr versus 118 mL/hr with placebo

(p<0.0001).

Despite the faster rate of LR infusion into the HYLENEX-assisted arms, the

HYLENEX arms demonstrated significantly less edema in all HYLENEX dose

groups and all timepoints during infusions. Across the three HYLENEX dose

cohorts, 94% of subjects had moderate or severe arm edema with placebo

compared to 17% with HYLENEX (p < 0.0001).

AEs occurring following treatment were mild to moderate in severity,

localized to the infusion sites, and evenly distributed between placebo

and HYLENEX treatment arms. There were no severe or serious AEs.

In the double-blinded global preference ranking, both study subjects and

the Investigator preferred, in 92% of cases across the three dose cohorts,

the HYLENEX-assisted arms for Sub-Q infusions rather than placebo arms

(p < 0.0001).

The Journal of Palliative Medicine is an interdisciplinary journal that reports on the clinical, educational, legal, and ethical aspects of care for seriously ill and dying patients. It includes coverage of the latest developments in drug and non-drug treatments for patients with life-threatening diseases. The journal reports on the development of palliative care programs around the U.S. and the world and innovation in palliative care education.

HYLENEX is a liquid injectable drug product formulation that includes the active pharmaceutical ingredient recombinant human hyaluronidase (rHuPH20) and is approved by the U.S. Food and Drug Administration (FDA) for use as a spreading agent to increase the absorption and dispersion of other injected drugs and for Sub-Q fluid administration. HYLENEX is the first and only FDA-approved hyaluronidase from a recombinant human source. Sub-Q hydration is the introduction of fluids under the skin to replace inadequate intake or excessive loss of water and electrolytes during illness or operation.

About HYLENEX

HYLENEX recombinant (hyaluronidase human injection, rHuPH20) is indicated as an adjuvant to increase the absorption and dispersion of other injected drugs, as an adjuvant for subcutaneous fluid administration (hypodermoclysis), and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents. Hyaluronidase is contraindicated in patients with hypersensitivity to hyaluronidase enzyme or any other ingredients in the formulation. Hyaluronidase should not be used to enhance the absorption and dispersion of dopamine and/or alpha agonist drugs. Discontinue HYLENEX recombinant if sensitization occurs. Hyaluronidase should not be applied directly to the cornea, and should not be injected around infected or acutely inflamed areas, nor used to reduce the swelling of bites or stings. Hyaluronidase should not be used for intravenous injections because the enzyme is rapidly inactivated. Furosemide, the benzodiazepines, and phenytoin are incompatible with hyaluronidase. For more information about HYLENEX please visit http://www.HYLENEX.com or call 1-800-262-3784. HYLENEX is a trademark of Baxter International Inc.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

Safe Harbor Statement

In addition to historical information, the statements set forth above include forward-looking statements (including, without limitation, statements concerning HYLENEX clinical trial results) that involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including regulatory approval requirements and competitive conditions. These and other factors that may result in differences are discussed in greater detail in the company's reports on Forms 10-K, 10-Q, and other filings with the Securities and Exchange Commission.

Halozyme Contact Media Contacts

David A. Ramsay Karen Sparks / Joleen Schultz

Chief Financial Officer Mentus

(858) 704-8260 (858) 455-5500, x275/x215

dramsay@halozyme.com karen@mentus.com

jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer
2. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
3. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
4. Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
5. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
6. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
7. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
8. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
9. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
10. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
11. The Pittsburgh Life Sciences Greenhouse Relocates Therapeutics Company to Pittsburgh
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):